Theriva Biologics, Inc.
TOVX
$1.42
$0.00780.55%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -13.22% | -16.04% | -20.58% | -7.59% | 2.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.96% | -5.53% | 4.84% | 10.09% | 14.22% |
| Operating Income | 14.96% | 5.53% | -4.84% | -10.09% | -14.22% |
| Income Before Tax | -28.33% | -28.61% | -5.17% | 6.00% | 5.31% |
| Income Tax Expenses | -- | 76.10% | 39.89% | 25.36% | -15.09% |
| Earnings from Continuing Operations | -39.80% | -38.23% | -8.65% | 4.29% | 6.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.80% | -38.23% | -8.65% | 4.29% | 6.78% |
| EBIT | 14.96% | 5.53% | -4.84% | -10.09% | -14.22% |
| EBITDA | 15.06% | 5.70% | -4.69% | -9.93% | -14.03% |
| EPS Basic | 7.00% | -7.30% | 7.40% | 10.87% | 12.16% |
| Normalized Basic EPS | 42.26% | 20.84% | 6.72% | -2.12% | -4.19% |
| EPS Diluted | 7.00% | -7.30% | 7.40% | 10.87% | 12.16% |
| Normalized Diluted EPS | 42.26% | 20.84% | 6.72% | -2.12% | -4.19% |
| Average Basic Shares Outstanding | 109.17% | 29.89% | 14.12% | 6.13% | 5.09% |
| Average Diluted Shares Outstanding | 109.17% | 29.89% | 14.12% | 6.13% | 5.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |